Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Other Working Capital Changes: 2013-2025

Historic Other Working Capital Changes for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to -$1.9 million.

  • Theravance Biopharma's Other Working Capital Changes fell 263.33% to -$1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.4 million, marking a year-over-year decrease of 226.47%. This contributed to the annual value of -$7.4 million for FY2024, which is 198.04% down from last year.
  • Latest data reveals that Theravance Biopharma reported Other Working Capital Changes of -$1.9 million as of Q3 2025, which was down 9.59% from -$1.7 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Other Working Capital Changes registered a high of $10.9 million during Q4 2023, and its lowest value of -$4.0 million during Q1 2024.
  • Moreover, its 3-year median value for Other Working Capital Changes was -$1.6 million (2023), whereas its average is -$461,545.
  • Per our database at Business Quant, Theravance Biopharma's Other Working Capital Changes spiked by 427.25% in 2023 and then slumped by 266.86% in 2024.
  • Quarterly analysis of 5 years shows Theravance Biopharma's Other Working Capital Changes stood at -$2.8 million in 2021, then skyrocketed by 173.14% to $2.1 million in 2022, then soared by 427.25% to $10.9 million in 2023, then slumped by 129.67% to -$3.2 million in 2024, then slumped by 263.33% to -$1.9 million in 2025.
  • Its last three reported values are -$1.9 million in Q3 2025, -$1.7 million for Q2 2025, and -$1.7 million during Q1 2025.